OakChart

Ligand Pharmaceuticals Inc

LGNDHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 10:20 AM ET

317.50+3.34 (1.06%)
2026-11-11 16:21 CET
Market cap
6,284.14 USD m
Revenue, TTM
253.83 USD m
Net income, TTM
51.46 USD m
Free cash flow, TTM
90.63 USD m
EPS diluted, TTM
2.24
P/E
141.62
Compare

Price

LGND against its 20, 50 and 200-day averages
2050200beatmiss
200.00250.00300.001.1M2.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LGNDclose 317.5020-day 309.5250-day 300.76200-day 257.17317.50

2.8% under 326.63 on 8 Jul 2026. Last 15 sessions, 9.5% high to low

Profile

LGND
52-week range, 94% of the way up
175.89326.63

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

IndexRUT
Employees47
IPONov 18, 1992
Beta1.21
ATR, 14d11.29
Rel volume0.25
Short float12.62%
Insider own2.42%
Inst own114.33%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap6.35B
Enterprise Value7.05B
Income51.46M
Sales253.83M
Book/sh48.09
Cash/sh22.57
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJul 02, 2010
Dividend Gr. 3/5Y- -
Payout0.00%
Employees47
IPONov 18, 1992

Ratios

P/E141.62
Forward P/E26.56
PEG1.32
P/S25.02
P/B6.60
P/C14.07
P/FCF70.08
EV/EBITDA95.99
EV/Sales27.79
Quick Ratio1.19
Current Ratio1.22
Debt/Eq1.20
LT Debt/Eq0.73
Option/ShortYes / Yes

Earnings

EPS (ttm)2.24
EPS next Y11.95
EPS next Q2.88
EPS this Y17.85%
EPS next Y24.77%
EPS next 5Y20.09%
EPS past 3/5Y- -
Sales past 3/5Y10.96% 7.54%
EPS Y/Y TTM8.35%
Sales Y/Y TTM1.03%
EPS Q/Q-125.10%
Sales Q/Q-31.80%
EarningsOct 29 BMO
EPS/Sales Surpr.14.66% 2.26%

Ownership

Insider Own2.42%
Insider Trans-16.13%
Inst Own114.33%
Inst Trans9.55%
ROA2.77%
ROE5.38%
ROIC3.09%
Gross Margin81.63%
Oper. Margin14.38%
Profit Margin20.27%
SMA202.58%
SMA505.57%
SMA20023.46%
Trades-

Technical

Shs Outstand20.00M
Shs Float19.52M
Short Float12.62%
Short Ratio10.60
Short Interest2.46M
52W High326.63 -2.80%
52W Low175.89 80.51%
Volatility4.10% 3.72%
ATR (14)11.29
RSI (14)56.20
Beta1.21
Rel Volume0.25
Avg Volume232.46K
Volume9,790

Performance

Perf Week0.43%
Perf Month4.60%
Perf Quarter9.93%
Perf Half Y43.53%
Perf YTD67.93%
Perf Year52.13%
Perf 3Y473.31%
Perf 5Y203.46%
Perf 10Y360.49%
Recom1.09
Target Price361.27
Prev Close314.16
Price317.50
Change %1.06%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 25, 2026InitiatedBBarclaysOverweight$345+8.7%
Aug 14, 2026InitiatedLLeerink PartnersOutperform
Jul 21, 2026ResumedCCitigroupBuy$387+21.9%
Mar 11, 2026InitiatedBBofA SecuritiesBuy$244-23.1%
Dec 09, 2025InitiatedCCitigroupBuy$270-15.0%
Apr 10, 2025InitiatedSStifelBuy$143-55.0%
Oct 03, 2024InitiatedOOppenheimerOutperform$135-57.5%
Jul 30, 2024InitiatedRRBC Capital MktsOutperform$130-59.1%
Apr 14, 2021ResumedSStephensOverweight$200-37.0%
Feb 04, 2021ReiteratedHH.C. WainwrightBuy$229 → $310-2.4%

Peers

Mkt cap
TickerCompanyMkt cap
RPRXRoyalty Pharma plc39.70B
HALOHalozyme Therapeutics Inc11.46B
INVAInnoviva Inc1.33B
OABIOmniAb Inc742.43M
ABCLAbCellera Biologics Inc4.13B
IONSIonis Pharmaceuticals Inc4.78B
ARWRArrowhead Pharmaceuticals Inc6.79B
PTCTPTC Therapeutics Inc5.36B
EXELExelixis Inc17.10B
ANIPANI Pharmaceuticals Inc1.65B

Insider trading

latest 14 of 85
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Aryeh JasonDirectorNov 10 '26Proposed Sale320.033,000960,084Nov 10 02:25 PM
Aryeh JasonDirectorNov 04 '26Sale319.9928290,237108,476Nov 06 05:41 PM
Aryeh JasonDirectorNov 04 '26Proposed Sale319.9528290,226Nov 04 04:42 PM
Reardon AndrewCLO & SecretaryNov 02 '26Option Exercise52.275,000261,35036,854Nov 04 04:23 PM
Reardon AndrewCLO & SecretaryNov 02 '26Sale313.225,0001,566,09431,854Nov 04 04:23 PM
Aryeh JasonDirectorOct 30 '26Sale320.241,411451,860109,458Nov 03 07:39 PM
Aryeh JasonDirectorNov 02 '26Sale320.43700224,298108,758Nov 03 07:39 PM
Aryeh JasonDirectorNov 02 '26Proposed Sale316.56700221,595Nov 02 04:26 PM
JASON M ARYEHDirectorOct 30 '26Proposed Sale318.601,209385,185Oct 30 04:37 PM
Aryeh JasonDirectorOct 30 '26Proposed Sale320.4920264,738Oct 30 03:38 PM
Reardon AndrewCLO & SecretaryOct 02 '26Option Exercise52.2734017,77236,854Oct 06 04:35 PM
Reardon AndrewCLO & SecretaryOct 02 '26Sale304.075,0001,520,34631,854Oct 06 04:35 PM
Zimmermann MartineDirectorSep 10 '26Sale285.001,200342,0003,897Sep 14 04:59 PM
MARTINE ZIMMERMANNDirectorSep 10 '26Proposed Sale285.001,200342,000Sep 10 04:01 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XSMOInvesco S&P SmallCap Momentum ETFAUM: 2.74B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B

News

latest 14 of 206
  • Ligand's Royalty Engine Drives A Clean EPS Beat And Second Guidance Raise, But Held Revenue Outlook And A Heavier Balance Sheet Temper The Story (Earnings Whispers)
  • Ligand: Q3 Earnings Snapshot (Associated Press)
  • Ligand Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Ligand to Participate in November Investor Conferences (GlobeNewswire)
  • Ligand to Host Investor Day on December 8, 2026 (GlobeNewswire)
  • Loading…
  • Ligand's First Clean Look At Zoma Tests A Raised Profit Floor Wall Street Hasn't Matched (Earnings Whispers)
  • Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 (GlobeNewswire)
  • Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls (The Fly)
  • Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million (GlobeNewswire)
  • Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners (PR Newswire)
  • Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea from Sydnexis for $23 Million (GlobeNewswire)
  • Ligand to Participate in September Investor Conferences (GlobeNewswire)
  • Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ... (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-292.6702.329-1.43078.7577.0010
2026Q22026-08-062.3702.0102.22163.6961.309
2026Q12026-05-071.6301.816-0.67151.7258.707
2025Q42026-02-262.0201.4972.11959.6755.597
2025Q32025-11-063.0901.9285.685115.4658.746
2025Q22025-08-071.6001.4210.24347.6343.877
2025Q12025-05-081.3301.212-2.21245.3338.716
2024Q42025-02-271.2701.190-1.63842.8139.037
2024Q32024-11-071.8401.347-0.38951.8140.607
2024Q22024-08-061.4001.056-2.88041.5333.045
2024Q12024-05-071.2000.8344.75330.9827.924
2023Q42024-02-271.3800.6611.02928.1025.654
2023Q32023-11-081.0200.620-0.59132.8727.225
2023Q22023-08-081.4200.6360.12926.3724.745
2023Q12023-05-042.2800.8942.33443.9833.555
2022Q42023-02-220.7500.773-1.03550.3844.096

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.9941.93631.852120.28118.19
2020FY2.9362.531-0.184186.42173.06
2021FY4.1433.8653.313277.13269.76
2022FY2.4402.794-1.978196.25203.95
2023FY6.0905.3502.937131.31128.89
2024FY5.7405.656-0.220167.13163.37
2025FY8.1307.5806.130268.09264.01
2026FY-9.582--291.96
2027FY-11.955--384.46
2028FY-14.080--456.81
2029FY-17.067--550.29
2030FY-19.880--673.91

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0495397.8091.68103.08
2026Q4S2026-10-3094397.0291.68102.6
2026Q4S2026-10-2994397.0491.68102.6
2026Q4S2026-10-2590197.3489.60104.12
2026Q4S2026-10-2091197.3489.60104.12
2026Q4S2026-10-1994197.3489.60104.12
2026Q4S2026-10-1893197.2789.60104.12
2026Q4S2026-09-3094197.2789.60104.12
2026Q4S2026-09-2695197.2789.60104.12
2026Q4S2026-09-2296197.2789.60104.12
2026Q4S2026-08-1698097.3589.60104.12
2026Q4S2026-08-13108096.4988.75104.12
2026Q4S2026-08-1198096.5888.75104.12
2026Q4S2026-08-0797096.4188.75104.12

Estimate history

EPS, annual0.5355.95531.852-0.1843.313-1.9782.937-0.226.1332.2419
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.389-1.638-2.2120.2435.6852.119-0.6712.221-1.427
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual141.102251.453120.282186.419241.544196.245131.314167.133268.087253.83
Period201720182019202020212022202320242025TTM
Sales, quarterly51.81242.81245.33347.627115.46159.66651.72263.69378.746
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.14920.76616.82316.0816.76716.95117.55619.10619.77420.001
Period201720182019202020212022202320242025MRQ
Shares, quarterly18.7619.10619.27619.41119.65619.77420.02919.9220.001
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue253.83268.09167.13131.31196.25241.54186.42120.28251.45
Cost of Goods Sold Incl. D&A46.6247.2646.3343.2977.1096.2756.1453.5822.13
Gross Profit207.20220.83120.8088.03119.14145.27130.2866.70229.32
Selling, General and Administrative Excl. Other170.90174.83102.9878.20106.3179.02121.5572.4265.60
Research and Development23.0981.1821.4325.4136.2532.2357.1230.5427.86
Other Operating Expense-0.20-1.20-5.200.000.000.000.000.000.00
Operating Income36.5147.2023.029.8212.8466.258.73-5.72163.73
Interest Expense8.184.713.040.661.8019.6227.4235.7448.28
Unusual Expense37.81-84.4792.310.005.617.303.0012.80-5.40
Net Income Before Taxes52.73158.962.5263.6636.0172.20-10.54796.64173.33
Income Taxes1.2734.516.559.8441.23-4.15-7.55167.3430.01
Consolidated Net Income51.46124.45-4.0353.82-5.2276.35-2.98629.30143.32
Net Income From Continuing Operations51.46124.45-4.0353.82-5.2276.35-2.98629.30143.32
Net Income51.46124.45-4.0352.15-33.3657.14-2.98629.30143.32
EPS (Recurring)3.903.223.312.94-1.753.61-0.0532.315.80
EPS (Basic, Before Extraordinaries)2.596.44-0.223.02-1.983.44-0.1833.136.77
EPS (Diluted)2.246.13-0.222.94-1.983.31-0.1831.855.96
EBITDA73.4880.9060.4147.2356.23107.5936.7038.01180.42
Non-Operating Income (Expense)62.2132.0074.8554.4930.5832.8811.15850.9052.48
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense53.3637.0132.4620.3440.2021.4122.4319.3716.47
Price To Earnings Ratio140.13140.1342.6385.36-28.18-2.1714.77
Price To Sales Ratio24.5714.3111.739.665.7411.038.6317.1312.99
Gross Margin81.6382.3772.2867.0360.7160.1469.8955.4591.20
Operating Margin14.3817.6113.777.486.5427.434.68-4.7665.11
Net Margin20.2746.42-2.4139.72-17.0023.66-1.60523.1957.00
Shares Outstanding20.0019.7719.1117.5616.9516.7716.0816.8220.77
Market Capitalization6,284.146,284.142,024.641,245.281,128.491,574.19975.331,117.061,758.91

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue78.7563.6951.7259.67115.4647.6345.3342.81
Cost of Goods Sold Incl. D&A12.8611.3111.3711.0911.9011.1613.1111.10
Gross Profit65.8952.3840.3548.58103.5636.4632.2331.72
Selling, General and Administrative Excl. Other75.3843.7922.9828.7449.6627.1469.2930.33
Research and Development2.7714.672.153.5121.026.5750.094.42
Other Operating Expense0.000.000.00-0.20-0.20-0.40-0.40-0.30
Operating Income-9.498.5917.3720.0454.109.72-36.661.69
Interest Expense2.901.751.751.780.911.150.870.88
Unusual Expense33.49-37.1350.03-8.59-76.721.282.5616.62
Net Income Before Taxes-44.0964.30-24.2656.78141.1411.22-50.18-39.20
Income Taxes-15.6115.80-10.9112.0023.866.38-7.73-8.11
Consolidated Net Income-28.4848.51-13.3544.78117.274.85-42.45-31.09
Net Income From Continuing Operations-28.4848.51-13.3544.78117.274.85-42.45-31.09
Net Income-28.4848.51-13.3544.78117.274.85-42.45-31.09
EPS (Recurring)-0.251.031.091.833.080.29-2.12-1.03
EPS (Basic, Before Extraordinaries)-1.432.42-0.672.275.990.25-2.21-1.64
EPS (Diluted)-1.432.22-0.672.125.680.24-2.21-1.64
EBITDA1.9517.2926.0628.1862.8518.65-27.3210.90
Non-Operating Income (Expense)1.7920.3310.1529.9411.233.93-10.10-23.38
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense22.9310.798.3711.2711.657.906.195.94
Price To Earnings Ratio140.1342.8634.2291.00---42.63
Price To Sales Ratio24.5723.7614.4614.9114.5512.0811.1212.16
Gross Margin83.6882.2478.0281.4289.7076.5671.0974.08
Operating Margin-12.0513.4933.5833.5946.8520.41-80.873.94
Net Margin-36.1776.16-25.8075.06101.5710.18-93.64-72.62
Shares Outstanding20.0019.9220.0319.7719.6619.4119.2819.11
Market Capitalization6,284.146,334.793,981.243,721.223,471.342,193.362,024.512,024.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments733.52256.17170.31211.87341.11411.531,070.60767.19201.66
Short Term Receivables61.0542.4539.3135.0491.6559.0641.7555.8529.97
Inventories9.1314.1123.9713.2927.3326.497.307.124.37
Other Current Assets28.5818.833.843.404.673.484.0040.381.02
Total Current Assets832.27331.56237.43263.60464.75500.561,123.64870.54237.02
Net Property, Plant & Equipment10.7924.8125.0627.4932.6037.1717.545.374.21
Total Investments and Advances179.4321.4948.320.000.000.000.000.006.44
Long-Term Note Receivable4.16--------
Intangible Assets523.86556.92470.27458.31492.47795.97325.77337.90334.07
Deferred Tax Assets8.350.070.218.5335.7324.3225.6198.49136.05
Other Assets1.796.925.924.74272.034.272.360.474.86
Total Assets1,560.64941.77787.22762.671,297.591,362.291,494.911,312.77722.65
Short Term Debt Incl. Current Port. of LT Debt1.091.290.4177.411.418.481.2426.43224.53
Accounts Payable3.245.232.435.318.403.782.424.182.26
Income Tax Payable1.241.20-------
Other Current Liabilities31.8829.3913.9516.0931.8587.8513.3451.6312.08
Total Current Liabilities37.4537.1116.7898.8141.66100.1117.0082.25238.87
Long Term Debt450.405.825.7510.34322.97447.94648.93609.8618.86
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities52.6132.5231.6230.6130.8664.6032.9451.9751.63
Other Liabilities2.9835.8832.1425.4280.9440.1228.827.7813.51
Total Liabilities543.42111.3386.30165.18476.43652.76727.68751.86322.86
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,017.21830.44700.91597.49821.16709.52767.23560.91399.79
Total Shareholders Equity1,017.21830.44700.91597.49821.16709.52767.23560.91399.79
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,017.21830.44700.91597.49821.16709.52767.23560.91399.79
Total Liabilities & Stockholders Equity1,560.64941.77787.22762.671,297.591,362.291,494.911,312.77722.65
Book Value Per Share51.4443.4639.9235.2548.9744.1245.6127.0118.90
Tangible Book Value Per Share24.9514.3213.148.2119.60-5.3826.2410.743.11
Full-Time Employees4768587615415511511639
Price to Book Ratio6.532.391.861.381.921.371.393.064.37
Return on Assets9.95-0.476.94-0.515.74-0.2144.8314.081.90
Return on Equity13.47-0.538.29-0.749.98-0.4094.7629.843.39
Return on Invested Capital8.48-0.487.38-5.494.99-0.2644.4412.243.00
Quick Ratio21.988.5512.722.5310.504.7465.6610.500.97
Current Ratio22.238.9314.152.6711.155.0066.0910.580.99

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income51.46124.45-4.0352.15-33.3657.14-2.98629.30143.32
Depreciation37.5335.7237.3737.3856.8955.7927.9743.7314.72
Other Funds (Non Cash)43.92-120.8359.73-18.2027.9231.5058.72-772.9848.07
Funds from Operations130.4562.0277.2783.0372.17135.8064.65-25.12235.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-39.41-12.6619.36-34.4065.68-57.00-10.06-4.21-41.78
Cash from Operating Activities91.0349.3696.6248.63137.8578.8054.59-29.34194.06
Capital Expenditures-33.56-11.31-19.64-53.85-17.92-8.76-4.46-2.55-10.89
Net Assets From Acquisitions-782.85-8.09-92.00-10.400.000.00-404.88-11.84-5.86
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments156.02-353.5830.9252.15182.4140.01615.67-326.82-409.44
Purchase of Investments-618.36-730.86-231.58-142.01-51.98-181.32-423.02-2,357.55-1,434.26
Sale Or Maturity of Investments774.38377.28262.50194.17234.39221.341,038.692,030.731,024.82
Other Uses-64.53-14.61-77.500.00-0.96-1.220.00-4.67-1.00
Other Sources55.5910.2614.550.420.090.4925.32812.803.91
Cash from Investing Activities-669.33-377.32-143.66-11.68163.6230.52231.65466.92-423.27
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock85.2899.89102.7322.453.2315.32-74.98-450.43-42.78
Repurchase of Common Pref Stock-60.00-15.000.000.000.00-18.45-78.00-453.43-152.96
Sale of Common Pref Stock145.28114.89102.7322.453.2333.763.023.00110.18
Proceedsfrom Stock Options114.1067.3937.140.000.000.000.000.000.00
Issuance or Reduction of Debt, Net488.78338.11-0.03-76.90-260.80-146.01-231.76-14.92814.74
Change in Long Term Debt488.78338.11-0.03-76.90-260.80-146.01-231.76-14.92814.74
Issuance of Long Term Debt684.60451.380.000.000.2018.940.0012.401,172.66
Reduction of Long Term Debt-195.82-113.28-0.03-76.90-261.00-164.95-231.76-27.32-357.92
Net Financing Active Other Cash Flow-29.36-9.77-5.14-4.55-18.42-7.07-3.81-19.82-443.37
Other Financing Activities Uses-22.45-9.77-5.14-4.55-18.42-7.07-3.81-19.82-443.37
Cash from Financing Activities544.69428.2297.57-59.00-275.99-137.76-310.55-485.17328.58
Exchange Rate Effect-2.382.36-1.17--0.000.000.08-
Net Change in Cash-35.99102.6249.35-22.0525.48-28.44-24.31-47.5199.38
Free Cash Flow90.6348.9194.8045.11119.9370.0450.13-31.89193.17
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow68.8078.4520.6728.129.4038.0332.11-16.91
Deferred Taxes & Investment Tax Credit-22.68-15.8011.7020.72-8.62-19.0574.8329.74

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments451.511,357.76779.42733.52664.52245.02
Short Term Receivables107.5269.9254.8061.0558.1042.12
Inventories14.5110.2613.279.1311.9015.49
Other Current Assets34.7019.1717.9328.5819.4050.32
Total Current Assets608.231,457.12865.41832.27753.92352.94
Net Property, Plant & Equipment24.229.8410.2810.7911.0711.62
Total Investments and Advances209.37169.43128.09179.43158.0728.87
Intangible Assets1,282.52505.01512.42523.86541.41545.23
Deferred Tax Assets104.1237.128.478.359.530.83
Other Assets2.932.002.711.792.779.11
Total Assets2,237.462,185.881,532.111,560.641,476.77948.60
Short Term Debt Incl. Current Port. of LT Debt452.871.081.091.091.091.11
Accounts Payable4.099.405.263.243.688.58
Income Tax Payable2.753.221.891.241.280.30
Other Current Liabilities40.8633.0332.4231.8824.4954.73
Total Current Liabilities500.5746.7440.6737.4530.5464.73
Long Term Debt701.341,130.37450.89450.40449.914.63
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities39.6838.8439.6952.6122.6732.25
Other Liabilities34.102.423.542.9823.4818.47
Total Liabilities1,275.701,218.36534.78543.42526.60120.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity961.76967.52997.321,017.21950.17828.53
Total Shareholders Equity961.76967.52997.321,017.21950.17828.53
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity961.76967.52997.321,017.21950.17828.53
Total Liabilities & Stockholders Equity2,237.462,185.881,532.111,560.641,476.77948.60
Book Value Per Share48.0948.5749.7951.4448.3442.68
Tangible Book Value Per Share-16.0423.2224.2124.9520.8014.59
Full-Time Employees---47--
Price to Book Ratio6.536.353.883.914.152.75
Return on Assets2.7712.5812.609.954.00-8.36
Return on Equity5.3821.9617.1313.475.42-9.46
Return on Invested Capital-1.712.31-0.923.058.380.58
Quick Ratio1.1930.9620.9521.9824.305.21
Current Ratio1.2231.1821.2822.2324.695.45

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-28.4848.51-13.3544.78117.274.85
Depreciation11.458.708.708.698.758.93
Other Funds (Non Cash)49.52-39.1760.99-27.42-123.538.51
Funds from Operations20.0031.0242.8136.6323.7821.97
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-47.59-7.005.889.29-10.62-6.17
Income Taxes Payable-21.82-0.170.69-0.862.42
Cash from Operating Activities-27.5924.0248.6945.9113.1615.80
Capital Expenditures-30.01-2.67-0.23-0.66-8.41-0.21
Net Assets From Acquisitions-782.850.000.000.00-8.090.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-51.94323.32-101.53-13.83-338.67-12.48
Purchase of Investments-141.78-38.40-222.18-216.01-392.14-63.34
Sale Or Maturity of Investments89.84361.72120.65202.1853.4750.86
Other Uses-56.75-2.670.00-5.11-1.870.00
Other Sources43.553.137.411.503.592.03
Cash from Investing Activities-877.99321.12-94.35-18.10-353.44-10.67
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.6262.707.659.3078.138.24
Repurchase of Common Pref Stock0.00-60.000.000.00-15.000.00
Sale of Common Pref Stock5.62122.707.659.3093.138.24
Proceedsfrom Stock Options114.100.000.000.0067.390.00
Issuance or Reduction of Debt, Net-1.53484.03-0.016.29331.83-0.01
Change in Long Term Debt-1.53484.03-0.016.29331.83-0.01
Issuance of Long Term Debt-1.52679.830.006.29445.090.00
Reduction of Long Term Debt-0.01-195.80-0.01-0.01-113.26-0.01
Net Financing Active Other Cash Flow-0.04-0.34-21.73-7.25-0.396.76
Other Financing Activities Uses-0.04-0.34-21.73-0.34-0.39-0.14
Cash from Financing Activities4.06546.43-14.138.33409.5715.00
Exchange Rate Effect-1.790.04-0.04-0.592.42-0.53
Net Change in Cash-903.31891.61-59.8335.5571.7119.60
Free Cash Flow-27.7323.9948.4645.9113.1515.58
Price to Free Cash Flow68.8052.4932.2581.72119.2642.56

Revenue breakdown

Capvaxive2024: 626.00K 2025: 10.06M
Filspari2024: 12.18M 2025: 31.97M
Financial Royalty, Other2024: 2.32M 2025: 4.73M
Income From Divestiture Transactions2025: 53.07M
License Fees2024: 1.94M 2025: 6.99M
Material Sales, Captisol, Core2024: 30.88M 2025: 40.21M
Ohtuvayre2024: 833.00K 2025: 9.76M
QARZIBA2024: 11.12M 2025: 23.74M
Royalty, Evomela2024: 8.68M 2025: 5.94M
Royalty, Kyprolis2024: 38.38M 2025: 35.53M
Royalty, Other2024: 7.49M 2025: 10.37M
Royalty, Rylaze2024: 13.74M 2025: 13.35M
Royalty, Teriparatide Injection2024: 8.22M 2025: 8.15M
Service2024: 25.53M 2025: 6.81M
Vaxneuvance2024: 5.18M 2025: 7.40M
United States2024: 167.13M 2025: 268.09M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.62%2.5M19.5M241.00K
2026-10-1512.86%2.5M19.5M251.46K
2026-09-3013.77%2.7M19.5M274.74K
2026-09-1513.53%2.6M19.5M355.68K
2026-08-3112.76%2.5M19.4M354.40K
2026-08-1412.59%2.4M19.5M359.84K
2026-07-3111.10%2.2M19.6M352.86K
2026-07-159.81%1.9M19.6M333.81K
2026-06-3010.85%2.1M19.6M312.91K
2026-06-158.63%1.7M19.6M220.30K
2026-05-298.38%1.6M19.6M228.71K
2026-05-157.70%1.5M19.6M223.95K
2026-04-307.45%1.5M19.5M219.47K
2026-04-157.24%1.4M19.4M222.66K
2026-03-317.70%1.5M19.4M224.82K
2026-03-137.51%1.5M19.4M216.42K
2026-02-277.10%1.4M19.4M210.43K
2026-02-137.15%1.4M19.2M219.96K
2026-01-306.68%1.3M19.2M231.95K
2026-01-156.60%1.3M19.2M219.77K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call110207211.9186.94.4261.000.000.962-1.0910.041
call115202206.90.004.2550.000.000.961-1.0880.042
call120197201.90.004.0920.000.000.959-1.0850.044
call125192196.90.003.9370.000.000.957-1.0810.045
call130187191.5116.63.7882.000.000.956-1.0760.047
call135182186.9129.63.6451.000.000.954-1.0720.049
call140177181.9158.43.5071.000.000.952-1.0670.050
call145172176.9127.23.3741.000.000.950-1.0610.052
call150167171.90.003.2470.000.000.948-1.0550.053
call155162166.9110.63.1231.000.000.946-1.0490.055
call160157161.80.003.0030.000.000.943-1.0420.057
call165152156.9120.62.8871.000.000.941-1.0350.059
call170147151.973.302.7750.000.000.939-1.0270.061
call175142146.976.902.6652.000.000.936-1.0190.062
call180137141.90.002.5590.000.000.934-1.0110.064
call185132136.90.002.5410.000.000.931-1.0020.066
call190127131.9120.22.4371.000.000.928-0.9930.068
call195122126.946.502.3362.000.000.925-0.9830.071
call200117121.7103.32.2373.000.000.922-0.9730.073
call210107111.856.602.0461.000.000.915-0.9510.078
call22097.00101.835.061.86210.000.000.908-0.9270.083
call23087.0091.8089.001.6852.000.000.899-0.9010.088
call24077.0081.8080.301.5134.000.000.889-0.8710.095
call25067.0071.8051.781.3469.000.000.877-0.8370.102
call26057.9061.8048.651.18227.000.000.863-0.7990.110
call27047.5051.9049.101.0210.000.000.845-0.7550.119
call28037.5042.3027.100.9001.000.000.822-0.7040.131
call29028.2033.0021.900.7709.000.000.790-0.6400.144
call30019.5024.3014.900.6695.000.000.738-0.5760.163
call31012.4016.5012.350.59611.000.000.627-0.5970.189
call3206.0010.5013.350.5793.000.000.484-0.6190.200
call3301.556.402.500.55521.000.000.343-0.5570.184
call3400.004.903.600.6493.000.000.266-0.5930.164
call3500.004.902.000.7713.000.000.231-0.6550.152
call3600.004.901.350.8897.000.000.208-0.7090.144
call3700.004.902.351.0032.000.000.190-0.7580.136
call3800.004.902.901.1103.000.000.177-0.7990.130
call3900.004.902.051.2111.000.000.166-0.8360.125
call4000.004.900.001.3060.000.000.156-0.8690.120
call4100.004.900.001.3970.000.000.149-0.8980.116
call4200.004.904.501.5021.000.000.144-0.9400.113
call4300.004.900.001.5710.000.000.136-0.9520.110
call4400.004.900.001.6510.000.000.132-0.9750.107
call4500.004.902.651.7281.000.000.127-0.9960.104
call4600.004.900.001.8030.000.000.123-1.0160.102
call4700.004.900.001.8740.000.000.120-1.0360.100
put1100.004.901.704.7893.000.00-0.038-1.0770.041
put1150.004.902.054.6073.000.00-0.039-1.0740.042
put1200.004.900.954.4333.000.00-0.041-1.0700.044
put1250.004.901.204.2670.000.00-0.043-1.0650.045
put1300.004.901.554.1092.000.00-0.045-1.0610.047
put1350.004.901.103.9562.000.00-0.046-1.0550.049
put1400.004.900.953.8097.000.00-0.048-1.0500.050
put1450.004.901.853.6684.000.00-0.050-1.0430.052
put1500.004.901.353.5327.000.00-0.052-1.0370.054
put1550.004.901.603.4006.000.00-0.054-1.0300.055
put1600.004.904.253.2734.000.00-0.057-1.0230.057
put1650.004.900.503.1503.000.00-0.059-1.0150.059
put1700.004.900.353.0302.000.00-0.061-1.0070.061
put1750.004.901.062.9222.000.00-0.063-1.0000.062
put1800.004.900.002.8030.000.00-0.066-0.9910.064
put1850.004.900.002.6990.000.00-0.069-0.9820.066
put1900.004.900.002.5910.000.00-0.072-0.9720.068
put1950.004.900.002.4860.000.00-0.074-0.9620.071
put2000.004.9014.872.3830.000.00-0.078-0.9520.073
put2100.004.902.322.1851.000.00-0.084-0.9290.078
put2200.004.903.101.99016.000.00-0.092-0.9030.083
put2300.004.903.251.81010.000.00-0.101-0.8760.088
put2400.004.905.081.63111.000.00-0.111-0.8450.095
put2500.004.902.811.4576.000.00-0.122-0.8110.102
put2600.004.9011.701.2862.000.00-0.137-0.7720.110
put2700.004.901.501.11720.000.00-0.154-0.7270.119
put2800.004.903.350.9502.000.00-0.177-0.6740.130
put2900.004.902.000.7812.000.00-0.207-0.6020.143
put3000.454.908.500.6071.000.00-0.255-0.5290.161
put3103.607.000.000.5230.000.00-0.377-0.5750.190
put3207.9011.0023.000.5154.000.00-0.516-0.5840.200
put33013.6017.0053.100.5020.000.00-0.657-0.5200.184
put34020.9025.000.000.5190.000.00-0.742-0.5240.162
put35029.6034.000.000.5690.000.00-0.769-0.6160.152
put36039.0043.500.000.6280.000.00-0.793-0.6710.143
put37048.8053.500.000.7140.000.00-0.810-0.7180.136
put38058.7063.5096.500.7920.000.00-0.824-0.7590.130
put39068.7073.500.000.8630.000.00-0.835-0.7940.124
put40078.5083.3090.500.9440.000.00-0.844-0.8260.120
put41088.6093.300.000.9720.000.00-0.851-0.8540.116
put42098.60103.50.001.0960.000.00-0.858-0.8800.113
put430108.7113.50.001.1840.000.00-0.864-0.9040.110
put440118.7123.50.001.2200.000.00-0.868-0.9260.107
put450128.6133.50.001.3040.000.00-0.873-0.9460.104
put460138.6143.50.001.3690.000.00-0.877-0.9660.102
put470148.6153.50.001.4130.000.00-0.880-0.9840.100

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-10SCHEDULE 13G/ASEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-03SCHEDULE 13D/ASEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-30144Filing for proposed sale of securities under Rule 144.SEC
2026-10-30144Filing for proposed sale of securities under Rule 144.SEC
2026-10-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-248-KCurrent report2026-09-24SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-10144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-09-028-K/A2026-07-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-13SCHEDULE 13GSEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-07-22S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.88M3
2026-10001.97M2
2026-09001.77M2
2026-080012.78M3
2026-07001.57M1
2026-06005.73M6
2026-05001.72M4
2026-04001.10M2
2026-03005.63M7
2026-020091.49K1
2026-010088.53K1
2025-1200431.17K2
2025-11002.30M3

Institutional holders

Manager% owned
BlackRock, Inc.15.47%
Invesco Ltd.6.00%
VANGUARD PORTFOLIO MANAGEMENT LLC5.68%
Jupiter Topco LLC5.19%
VANGUARD CAPITAL MANAGEMENT LLC4.35%
STATE STREET CORP4.12%
FRANKLIN RESOURCES INC3.75%
FMR LLC3.51%
CONGRESS ASSET MANAGEMENT CO3.30%
GEODE CAPITAL MANAGEMENT, LLC2.94%

Funds

Fund% owned
CALAMOS STRATEGIC TOTAL RETURN FUND93.21%
iShares Convertible Bond ETF77.59%
Calamos Growth & Income Fund70.13%
Columbia Convertible Securities Fund62.70%
CALAMOS CONVERTIBLE & HIGH INCOME FUND59.88%
Calamos Convertible Fund58.63%
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND57.38%
Calamos Dynamic Convertible & Income Fund47.40%
ABSOLUTE CONVERTIBLE ARBITRAGE FUND43.66%
Virtus Income & Growth Fund43.51%

OakChart. LGND. Cached 15 minutes.